Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Simcere Pharmaceutical

- PMLiVE

Keytruda and Opdivo backed for new uses in Europe

CHMP recommendations also include Trumenba, Dinutuximab beta and Refixia

- PMLiVE

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country's Priority Review pathway

Pharma China Annual Forum 2017

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Research Partnership

- PMLiVE

Keytruda claims first blood cancer OK from FDA

Merck & Co wins US approval for its haematological cancer treatment

Bristol-Myers Squibb (BMS) building

BMS replaces R&D head in wake of Opdivo setbacks

As Merck & Co’s Keytruda gains the lion’s share of the market

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

BMS appoints three independent directors

Robert Bertolini, Matthew Emmens and Theodore Samuels join the board

AstraZeneca AZ

Generic version of AZ’s Iressa launched in China

Qilu Pharma’s Yiruike licensed as first-line NSCLC treatment

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

Deal Watch January 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links